# Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

> **NCT00140725** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 160 (—)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Lamivudine plus Polyethylene glyco-interferon alfa-2b
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT00140725
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 160 (—)
- **Last updated:** 2008-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140725, "Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00140725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*